Baxter Clocks Better-Than-Expected Q4 Earnings, But FY22 Guidance Trail Street View


Baxter International Inc BAX has posted Q4 revenue of $3.5 billion, beating the consensus of $3.35 billion, up 10% on a reported basis, 12% on a constant currency basis, and 4% on an operational basis.

  • Adjusted EPS of $1.04 increased 30%, marginally ahead of the consensus of $1.03.
  • Following Baxter's acquisition of Hillrom, Baxter's Q4 and FY21 results include Hillrom's financial results for the last 19 days of the quarter. Hillrom added $212 million to Q4 sales.
  • Baxter's three geographic segments – Americas, EMEA, and APAC – all positively contributed to sales growth, reflecting ongoing demand for select Baxter products amid the pandemic, partially offset lower surgical procedures resulting from the emergence of omicron variant.
  • The gross margin improved from 37.4% to 40%, and the operating margin declined from 12.8% to 10.9%.
  • Outlook: Baxter expects FY22 sales growth of approximately 24% - 25% on a reported basis and around 4% on an operational basis. 
  • It expects an adjusted EPS of $4.25 - $4.35, versus the consensus of $4.36.
  • For Q1 FY22, Baxter expects an adjusted EPS of $0.79 - $0.82 compared to the Wall Street estimate of $0.97.
  • The Company forecasts sales growth of 1% - 3% on an operational basis.
  • Price Action: BAX shares are trading 2.30% lower at $83.17 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!